Literature DB >> 26787046

Severe Cerebral Vasospasm and Childhood Arterial Ischemic Stroke After Intrathecal Cytarabine.

Daniel Tibussek1, Rungrote Natesirinilkul2, Lisa R Sun3, Bruce A Wasserman4, Leonardo R Brandão2, Gabrielle deVeber5.   

Abstract

We report on 2 patients who developed widespread cerebral vasospasm and arterial ischemic strokes (AIS) after application of intrathecal (IT) cytarabine. In a 3-year-old child with acute lymphoblastic leukemia (ALL), left leg weakness, hyperreflexia, and clonus were noted 4 days after her first dose of IT cytarabine during the induction phase of her chemotherapy. Cerebral MRI revealed multiple acute cerebral ischemic infarcts and widespread cerebral vasospasm. A 5-year-old girl complained of right arm and leg pain and began limping 11 days after IT cytarabine. Symptoms progressed to right dense hemiplegia, left gaze deviation, headache, and speech arrest. MRI revealed 2 large cortical areas of diffusion restriction in the right frontal and left parietal lobes. Cerebral magnetic resonance angiography (MRA) showed irregular narrowing affecting much of the intracranial arterial circulation. Although the first child fully recovered from her neurologic symptoms, the second patient had persistent hemiplegia on follow-up. Including this report, there are now 4 pediatric ALL cases of severe cerebral vasospasm and AIS in the context of IT cytarabine administration, strongly suggesting a true association. Differential diagnosis and management issues are discussed. Along with the more widespread use of MRI and MRA, the true frequency of this severe adverse effect will become clearer in future. For any child with neurologic symptoms within hours or days of receiving IT cytarabine, a low threshold for cerebral imaging with MRI and MRA is recommended.
Copyright © 2016 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26787046     DOI: 10.1542/peds.2015-2143

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  4 in total

1.  Cerebrovascular disease after allogeneic hematopoietic stem cell transplantation: incidence, risk, and clinical outcome.

Authors:  Ting-An Lin; Jyh-Pyng Gau; Yao-Chung Liu; Po-Shen Ko; Hao-Yuan Wang; Sheng-Hsuan Chien; Chia-Jen Liu; Liang-Tsai Hsiao; Tzeon-Jye Chiou; Jin-Hwang Liu
Journal:  Int J Hematol       Date:  2019-03-12       Impact factor: 2.490

Review 2.  A clinically relevant model of focal embolic cerebral ischemia by thrombus and thrombolysis in rhesus monkeys.

Authors:  Di Wu; Jian Chen; Longfei Wu; Hangil Lee; Jingfei Shi; Mo Zhang; Yanhui Ma; Xiaoduo He; Zixin Zhu; Feng Yan; Chuanjie Wu; Yunxia Duan; Yongjuan Fu; Sijie Li; Xinglong Zhi; Xuxiang Zhang; Shengli Li; Yuchuan Ding; Xunming Ji
Journal:  Nat Protoc       Date:  2022-06-27       Impact factor: 17.021

Review 3.  Selective therapeutic cooling: To maximize benefits and minimize side effects related to hypothermia.

Authors:  Di Wu; Jian Chen; Xuxiang Zhang; Roxanne Ilagan; Yuchuan Ding; Xunming Ji
Journal:  J Cereb Blood Flow Metab       Date:  2021-10-20       Impact factor: 6.960

4.  Reversible cerebral vasoconstriction syndrome after intrathecal cytarabine.

Authors:  Natalia Trombini Mendes; Luiza Ramos de Freitas; Rônney Pinto Lopes; Lohana Santana Almeida da Silva; Francisco Tomaz Meneses de Oliveira
Journal:  Hematol Transfus Cell Ther       Date:  2020-12-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.